Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (I NaL ) SCN5A mutations that prolongs cardiac action potential (AP) and enhances I NaL current. Mexiletine inhibits I NaL and shortens the QT interval in LQT3 patients. Above therapeutic doses, mexiletine prolongs the cardiac AP. We explored structure–activity relationships (SAR) for AP shortening and prolongation using dynamic medicinal chemistry and AP kinetics in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Using patient-derived LQT3 and healthy hiPSC-CMs, we resolved distinct SAR for AP shortening and prolongation effects in mexiletine analogues and synthesized new analogues with enhanced potency and selectivity for I NaL . This resulted in compounds with decreased AP prolongation effects, increased metabolic stability, increased I NaL selectivity, and decreased avidity for the potassium channel. This study highlights using hiPSC-CMs to guide medicinal chemistry and “drug development in a dish”.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, ESCs raise an inextricable ethical issue, which largely hinders their utility [12,13].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [13]
In the citing paper
“Notably, by employing iPSC-derived cardiomyocytes, they found that new mexiletine analogues can enhance potency and selectivity for INa [13], discovering a potential new therapy for type-3 LQTS.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [13]
Citations
Cites
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
Wang, Q., Shen, J., Splawski, I., Atkinson, D., Li, Z., Robinson, J. L., Moss, A. J., Towbin, J. A., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90359-3 · Cited by 1,686
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Sudden Cardiac Death in the United States, 1989 to 1998
Zheng, Z.-J., Croft, J. B., Giles, W. H., & Mensah, G. A. (2001) · Circulation · doi:10.1161/hc4301.098254 · Cited by 1,596
Molecular mechanism for an inherited cardiac arrhythmia
Bennett, P. B., Yazawa, K., Makita, N., & George, A. L. (1995) · Nature · doi:10.1038/376683a0 · Cited by 957
Schwartz, P. J., Priori, S. G., Locati, E. H., Napolitano, C., Cantù, F., Towbin, J. A., Keating, M. T., Hammoude, H., Brown, A. M., Chen, L.-S. K., et al. (1995) · Circulation · doi:10.1161/01.cir.92.12.3381 · Cited by 816
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2017.10.035 · Cited by 669
Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia
Wang, Q., Shen, J., Li, Z., Timothy, K., Vincent, G. M., Priori, S. G., Schwartz, P. J., & Keating, M. T. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.9.1603 · Cited by 342
Long QT syndrome: from channels to cardiac arrhythmias
Moss, A. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25537 · Cited by 296
Self-citationMazzanti, A., Maragna, R., Faragli, A., Monteforte, N., Bloise, R., Memmi, M., Novelli, V., Baiardi, P., Bagnardi, V., Etheridge, S. P., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.033 · Cited by 254
Ventricular Tachycardia and Sudden Cardiac Death
Koplan, B. A., & Stevenson, W. G. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.289 · Cited by 206
Terrenoire, C., Wang, K., Chan Tung, K. W., Chung, W. K., Pass, R. H., Lu, J. T., Jean, J.-C., Omari, A., Sampson, K. J., Kotton, D. N., et al. (2013) · Journal of General Physiology · doi:10.1085/jgp.201210899 · Cited by 195
Self-citationThe clinical pharmacology of mexiletine.
Campbell, N. P. S., Kelly, J. G., Adgey, A. A., & Shanks, R. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb00833.x · Cited by 136
Small molecule fluorescent voltage indicators for studying membrane potential
Miller, E. W. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.003 · Cited by 126
Economic burden and co‐morbidities of atrial fibrillation in a privately insured population
Wu, E. Q., Birnbaum, H. G., Mareva, M., Tuttle, E., Castor, A. R., Jackman, W., & Ruskin, J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65475 · Cited by 125
Cerignoli, F., Charlot, D., Whittaker, R., Ingermanson, R., Gehalot, P., Savchenko, A., Gallacher, D. J., Towart, R., Price, J. H., McDonough, P. M., et al. (2012) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2012.08.167 · Cited by 112
Self-citationLu, H. R., Whittaker, R., Price, J. H., Vega, R., Pfeiffer, E. R., Cerignoli, F., Towart, R., & Gallacher, D. J. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv201 · Cited by 83
Kang, S., Han, J., Lee, E. S., Choi, E. B., & Lee, H. (2010) · Organic Letters · doi:10.1021/ol1017905 · Cited by 77
Id genes are essential for early heart formation
Cunningham, T. J., Yu, M. S., McKeithan, W. L., Spiering, S., Carrette, F., Huang, C.-T., Bushway, P. J., Tierney, M., Albini, S., Giacca, M., et al. (2017) · Genes & Development · doi:10.1101/gad.300400.117 · Cited by 74
Self-citationWang, D., Kiyosue, T., Sato, T., & Arita, M. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0084 · Cited by 71
McKeithan, W. L., Savchenko, A., Yu, M. S., Cerignoli, F., Bruyneel, A. A. N., Price, J. H., Colas, A. R., Miller, E. W., Cashman, J. R., & Mercola, M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00766 · Cited by 71
Self-citationBankston, J. R., Yue, M., Chung, W., Spyres, M., Pass, R. H., Silver, E., Sampson, K. J., & Kass, R. S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001258 · Cited by 58
Self-citationLuca, A. D., Natuzzi, F., Desaphy, J., Loni, G., Lentini, G., Franchini, C., Tortorella, V., & Camerino, D. C. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23198-9 · Cited by 56
Huang, K., Ortiz‐Marciales, M., Stepanenko, V., Jesús, M. D., & Correa, W. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo801181d · Cited by 47
Pharmacology and Clinical Use of Mexiletine
Fenster, P. E., & Comess, K. A. (1986) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1986.tb03442.x · Cited by 46
Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets
Karagueuzian, H. S., Pezhouman, A., Angelini, M., & Olcese, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00036 · Cited by 46
Self-citationHTS techniques for patch clamp-based ion channel screening – advances and economy
Farre, C., & Fertig, N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.682056 · Cited by 40
Gualdani, R., Tadini‐Buoninsegni, F., Roselli, M., Defrenza, I., Contino, M., Colabufo, N. A., & Lentini, G. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.160 · Cited by 39
Combined Modifications of Mexiletine Pharmacophores for New Lead Blockers of Nav1.4 Channels
Bellis, M. D., Luca, A. D., Desaphy, J., Carbonara, R., Heiny, J. A., Kennedy, A. R., Carocci, A., Cavalluzzi, M. M., Lentini, G., Franchini, C., et al. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2012.11.3830 · Cited by 29
Synthesis of (S)-Vasicol and (S)-3-Hydroxy-2-pyrrolidinone
Huang, P., Zheng, X., & Wei, H. (2003) · Heterocycles · doi:10.3987/com-03-9800 · Cited by 20
Hemodialysis as an alternative treatment of mexiletine intoxication
Akıncı, E., Yüzbaşıoğlu, Y., & Çoşkun, F. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2010.08.027 · Cited by 14
Structure–Activity relationships among novel phenoxybenzamine-Related β-Chloroethylamines
Giardinà, D., Crucianelli, M., Angeli, P., Buccioni, M., Gulini, U., Marucci, G., Sagratini, G., & Melchiorre, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00395-9 · Cited by 7
Research works printed but not linked: 4
- Singh S., 2020, Mexiletine
- Rudel R., 1994, Myology
- De Luca A., 2000, Mol. Pharmacol., 57, 268
- Alexander G. J., 1986, Neurobehav. Toxicol. Teratol., 8, 231
Cited by
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Self-citationUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“Using iPSC-derived cardiomyocytes from type-3 LQTS patients with SCN5A mutation revealed abnormal calcium transients with dimin- ished INa current density [11].”
BackgroundInfluentialSong, Y., Zheng, Z., & Lian, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889519 · Cited by 18
Synergistic FRET assays for drug discovery targeting RyR2 channels
Rebbeck, R. T., Ginsburg, K. S., Ko, C. Y., Fasoli, A., Rusch, K., Cai, G. F., Dong, X., Thomas, D. D., Bers, D. M., & Cornea, R. L. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.04.002 · Cited by 13
Gomez‐Galeno, J., Okolotowicz, K. J., Johnson, M., McKeithan, W. L., Mercola, M. A., & Cashman, J. R. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.828 · Cited by 8
Self-citation
Metadata
- Authors
- Cashman, J. R., Ryan, D., McKeithan, W. L., Okolotowicz, K., Gomez-Galeno, J., Johnson, M., Sampson, K. J., Kass, R. S., Pezhouman, A., Karagueuzian, H. S., & Mercola, M.
- Affiliations
- Human BioMolecular Research Institute (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Human BioMolecular Research Institute, San Diego, California 92121, United States
- Columbia University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Cashman, John R.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-05-04
- Volume
- 64
- Issue
- 9
- Pages
- 5384-5403
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3159519281
- Cited by
- 11
- References
- 32
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2022: 4 · 2021: 2
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- California Institute for Regenerative Medicine (TR4-06857)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- long QT syndrome type 3, mexiletine, sodium channel blockade, SCN5A mutation, ventricular arrhythmias, iPSC-derived cardiomyocytes, cardiac action potential, structure-activity relationship, drug repurposing, antiarrhythmic drugs
- MeSH terms
- Cardiac Conduction System Disease, Action Potentials, Animals, Anti-Arrhythmia Agents, Behavior, Animal, Cells, Cultured, Drug Stability, Half-Life, Humans, Long QT Syndrome, Male, Mexiletine, Mice, Inbred BALB C, Structure-Activity Relationship, Drug Design, Rats, Sprague-Dawley, Myocytes, Cardiac, Mice, Rats, Induced Pluripotent Stem Cells, NAV1.5 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.